By Billy Candra 
Cambridge researchers have unveiled groundbreaking findings demonstrating that bilateral salpingo-oophorectomy (BSO), a surgical procedure involving the removal of the ovaries and fallopian tubes, is associated with a substantial reduction in the risk of early death among women diagnosed with breast cancer who carry specific BRCA1 and BRCA2 genetic variants. The study, published in The Lancet Oncology, marks a pivotal moment in understanding the long-term benefits of this prophylactic surgery, particularly as it found no serious adverse side effects, addressing long-standing concerns about early menopause and its potential health ramifications.
Understanding BRCA Genes and Associated Risks
The BRCA1 and BRCA2 genes are integral to human health, playing crucial roles in DNA repair and maintaining genomic stability. When these genes undergo pathogenic variants (mutations), their ability to repair damaged DNA is compromised, significantly increasing an individual’s lifetime risk of developing certain cancers, most notably breast and ovarian cancers. For women carrying these variants, the statistics are stark: a lifetime risk of breast cancer can soar to 40-85%, while the risk of ovarian cancer, a particularly aggressive and often late-diagnosed disease, can reach 15-60%. These figures stand in stark contrast to the general population’s risks, underscoring the urgency for effective preventative strategies.
Historically, women identified as carriers of these high-risk variants, especially those who have already battled breast cancer, face complex decisions regarding risk-reduction strategies. The recommendation for BSO has been a cornerstone of preventative care for years, primarily aimed at mitigating the profound risk of ovarian cancer. Guidelines typically suggest BSO between the ages of 35 and 40 for BRCA1 carriers and between 40 and 45 for BRCA2 carriers, periods when the ovarian cancer risk begins to escalate significantly. Previous research had already established BSO’s efficacy in reducing ovarian cancer risk by as much as 80% in this population. However, a comprehensive understanding of its overall impact on long-term survival and potential unintended consequences, particularly for women with a prior breast cancer diagnosis, remained elusive.
The Procedure: Bilateral Salpingo-Oophorectomy (BSO) – A Preventative Measure
Bilateral salpingo-oophorectomy involves the surgical removal of both ovaries and fallopian tubes. For BRCA carriers, this procedure is considered a prophylactic measure, dramatically reducing the sites where ovarian cancer can originate. While highly effective in preventing ovarian cancer, BSO induces immediate surgical menopause, leading to an abrupt cessation of ovarian hormone production. This sudden hormonal shift has been a significant point of concern for patients and clinicians alike. The removal of the body’s primary source of oestrogen can trigger a range of menopausal symptoms, from hot flashes and night sweats to bone density loss and potential cardiovascular changes. For women with a history of breast cancer, the situation is further complicated by the fact that many may not be eligible for hormone replacement therapy (HRT) due to concerns about exacerbating their breast cancer risk, leaving them to manage menopausal symptoms without pharmaceutical aid. This complex interplay of benefits and potential drawbacks underscored the critical need for a large-scale study to evaluate the holistic impact of BSO.
Methodology: Navigating Ethical Challenges in Research
Traditionally, the ‘gold standard’ for assessing the efficacy and safety of medical interventions is through randomised controlled trials (RCTs). These trials involve randomly assigning participants to either a treatment group or a control group, allowing researchers to isolate the effects of the intervention. However, in the context of BRCA1 and BRCA2 carriers, particularly those with a history of breast cancer, conducting an RCT for BSO would be ethically untenable. Randomly assigning women at extremely high risk of a deadly cancer to a control group that would forgo a known effective preventative surgery would expose them to substantially greater and unacceptable risks of developing ovarian cancer.
To circumvent these ethical barriers while still generating robust evidence, a pioneering team at the University of Cambridge, in close collaboration with the National Disease Registration Service (NDRS) in NHS England, adopted an innovative approach. They leveraged the vast repositories of electronic health records and genetic testing data meticulously collected and curated by NDRS. This allowed them to conduct a large-scale, observational study, meticulously tracking the long-term outcomes of BSO among BRCA1 and BRCA2 pathogenic variant (PV) carriers who had been diagnosed with breast cancer. This methodology, while not an RCT, provided an unprecedented opportunity to analyse real-world data from a significant cohort, offering valuable insights that would otherwise be impossible to obtain.
The research identified a total of 3,400 women carrying one of the BRCA1 or BRCA2 cancer-causing variants, with approximately 1,700 women for each variant. Within this cohort, around 850 of the BRCA1 carriers and 1,000 of the BRCA2 carriers had undergone BSO surgery, providing a sufficiently large sample size for meaningful statistical analysis. The median follow-up period for the study was 5.5 years, allowing researchers to observe medium-to-long-term outcomes.
Key Findings: Beyond Ovarian Cancer Prevention
The study’s most significant revelation lies in its demonstration of a substantial reduction in the risk of early death among women who underwent BSO. Women in the study who had the procedure were approximately half as likely to die from cancer or any other cause during the follow-up period compared to those who did not. This overall survival benefit suggests that BSO’s protective effects extend beyond the prevention of ovarian cancer alone.
A more granular analysis revealed differences between the two gene variants:
- BRCA2 Carriers: Experienced a more pronounced reduction in early death risk, specifically a 56% decrease. This finding is particularly noteworthy given that BRCA2 is also strongly linked to male breast cancer, prostate cancer, and pancreatic cancer, though this study focused on female breast cancer patients.
- BRCA1 Carriers: Showed a 38% reduction in early death risk. While slightly less than BRCA2, this is still a highly significant and clinically meaningful outcome.
Beyond the reduction in mortality, the study also identified another critical benefit: women who underwent BSO were at approximately a 40% lower risk of developing a second primary cancer. This finding suggests a broader protective effect of ovarian hormone suppression, potentially impacting the development or recurrence of other hormone-sensitive cancers, including new primary breast cancers. While the researchers acknowledge that direct causation cannot be stated with 100% certainty from an observational study, the strength and consistency of the evidence strongly point towards BSO as the driving factor behind these improved outcomes.
Addressing Concerns: No Increased Risk of Other Conditions
One of the most reassuring aspects of the Cambridge study’s findings is the absence of a link between BSO and an increased risk of other long-term adverse health outcomes. Previous studies in the general population, where BSO might be performed for benign conditions or other reasons, have sometimes suggested an association with an increased risk of conditions like heart disease, stroke, or depression due to early menopause. However, for BRCA1 and BRCA2 carriers with a prior breast cancer diagnosis, this study found no such association. This crucial finding alleviates major concerns for both patients and clinicians, providing robust evidence that the survival benefits of BSO are not offset by an elevated risk of these common and debilitating conditions.
Hend Hassan, a PhD student at the Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, and Wolfson College, Cambridge, and the study’s first author, articulated this relief: "We know that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer, but there’s been a question mark over the potential unintended consequences that might arise from the sudden onset of menopause that this causes. Reassuringly, our research has shown that for women with a personal history of breast cancer, this procedure brings clear benefits in terms of survival and a lower risk of other cancers without the adverse side effects such as heart conditions or depression."
Expert Commentary and Clinical Significance
Professor Antonis Antoniou, from the Department of Public Health and Primary Care and the study’s senior author, emphasized the immediate clinical relevance of these findings. "Our findings will be crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation." This study provides concrete, data-driven evidence that can empower patients to make choices aligned with their long-term health goals, balancing the immediate challenges of surgical menopause with substantial, proven survival advantages.
The study’s results are expected to significantly influence clinical guidelines for managing BRCA1 and BRCA2 carriers, particularly those who have already faced a breast cancer diagnosis. The clear demonstration of an overall survival benefit and a reduced risk of secondary cancers strengthens the argument for BSO as a comprehensive risk-reduction strategy, moving it beyond just ovarian cancer prevention. Oncology teams, genetic counselors, and primary care physicians will now have more compelling data to present to patients during pre-operative discussions, providing a more holistic picture of the procedure’s benefits.
Addressing Disparities in Uptake
Despite the clear benefits, the study also highlighted concerning disparities in the uptake of BSO. The research found that most women undergoing BSO were white. Black and Asian women were approximately half as likely to have BSO compared to white women. Furthermore, women residing in less deprived areas showed a higher likelihood of undergoing BSO compared to those in the most-deprived categories.
These findings underscore significant health inequities that require urgent attention. Hassan commented on this disparity, stating, "Given the clear benefits that this procedure provides for at-risk women, it’s concerning that some groups of women are less likely to undergo it. We need to understand why this is and encourage uptake among these women." Potential factors contributing to these disparities could include differences in access to genetic testing and counseling, cultural beliefs surrounding surgery and fertility, socioeconomic barriers, language barriers, or even implicit biases within the healthcare system. Future research and public health initiatives must delve deeper into these causes to ensure equitable access to life-saving preventative care for all eligible women, regardless of their ethnicity or socioeconomic background. This involves targeted outreach, culturally sensitive counseling, and policies aimed at reducing systemic barriers to care.
The Power of NHS Data and Future Research
Professor Antoniou, who also directs the Cancer Data-Driven Detection programme, highlighted another crucial aspect of the study: "The study also highlights the power of exceptional NHS datasets in driving impactful, clinically relevant research." The collaboration with the National Disease Registration Service (NDRS) in NHS England exemplifies how robust, routinely collected healthcare data, when ethically accessed and meticulously analyzed, can provide invaluable insights into disease progression, treatment effectiveness, and long-term patient outcomes. This model of research holds immense potential for future studies, particularly in areas where traditional RCTs are not feasible or ethical.
The findings also open avenues for further research. While the study found no increased risk of heart disease, stroke, or depression, long-term monitoring beyond the 5.5-year median follow-up period could provide even more comprehensive data on highly rare or late-onset effects. Additionally, understanding the precise biological mechanisms behind the reduced risk of secondary cancers could lead to new therapeutic targets or preventative strategies for hormone-sensitive malignancies.
Funding and Broader Context
This vital research was made possible through funding from Cancer Research UK, a leading charity dedicated to saving lives through research, with additional support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre. Such collaborative funding underscores the national commitment to advancing cancer care and prevention.
In a broader context, the University of Cambridge and Addenbrooke’s Charitable Trust (ACT) are actively engaged in fundraising for a new hospital, the Cambridge Cancer Research Hospital. This ambitious project, a partnership with Cambridge University Hospitals NHS Foundation Trust, aims to revolutionize cancer diagnosis and treatment. While it will serve patients across the East of England, the research conducted within its walls promises to have a profound, far-reaching impact, changing the lives of cancer patients across the UK and globally. The findings from this latest BSO study represent a testament to the kind of life-changing research that such institutions are committed to fostering.
